This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J&J Reportedly May Buy Scios for $2 Billion

Johnson & Johnson (JNJ - Get Report) reportedly is in advanced talks to acquire biotech outfit Scios (SCIO) for about $2 billion.

Johnson & Johnson would pay about $45 a share of Scios, representing a 30% premium from its $34.69 close Thursday. In premarket trading, Scios shares surged 25% to $43.25, according to Instinet. Neither Johnson & Johnson nor Scios has issued any statements about the discussions, first reported in Friday's Wall Street Journal. The Journal noted that the two sides haven't agreed on a set price.

Scios has been a coveted commodity among the many Big Pharma players eager to partner up on its promising treatment for rheumatoid arthritis. At the J.P. Morgan H&Q conference last month, Scios Chief Executive Richard Brewer noted that the big drug makers have been paying visits to his company's headquarters.

With today's news, Johnson & Johnson appears to be in the pole position for an out-and-out acquisition, but other candidates may emerge.

The acquisition would be a boon for Johnson & Johnson, which has a history of scooping up smaller fry to keep its drug pipeline filled. Scios has one successful drug already -- Natrecor, a drug that treats patients suffering from congestive heart failure. Natrecor is expected to bring in up to $170 million in revenue this year.

Scios' rheumatoid arthritis treatment -- currently in phase II study -- looks very promising as well. The pill would have an advantage over Amgen's (AMGN) Enbrel and Abbott's (ABT) Humira, both of which are injected. The Journal noted that Scios' drug, if approved, would be a good fit with J&J's injected rheumatoid arthritis treatment, Remicade.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JNJ $112.62 -0.23%
SCIO $0.25 -3.85%
AAPL $92.20 -1.10%
FB $119.30 1.30%
GOOG $709.44 1.10%


Chart of I:DJI
DOW 17,686.22 +25.51 0.14%
S&P 500 2,050.14 -0.49 -0.02%
NASDAQ 4,710.2950 -6.7990 -0.14%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs